High Expression of NTRK1 in ETV6::RUNX1 Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to Larotrectinib
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31983 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Luke Quinlan und 12 weiteren Autor:innen. Beteiligte Einrichtung: South Australian Health and Medical Research Institute (SAHMRI), Blood Cancer Program, Precision Cancer Medicine Theme, Adelaide, South Australia, Au…. Hauptthemen laut MEDLINE: Receptor, trkA, Core Binding Factor Alpha 2 Subunit, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Pyrazoles. Die Arbeit nennt 32 Literaturangaben. Gefördert von: National Health and Medical Research Council, Medical Research Future Fund, Australia, Channel 7 Children's Research Fund.
Abstract (Originalsprache)
Background
ETV6 :: RUNX1 is one of the most common recurrent genomic abnormalities in acute lymphoblastic leukaemia (ALL) and is associated with a good prognosis. High expression of NTRK1 , encoding tropomyosin receptor kinase A (TrkA), confers a poor prognosis in other malignancies and may contribute to therapy resistance in patients with ETV6::RUNX1 B‐ALL.
Method
Relapse‐free survival was estimated by the Kaplan–Meier and log‐rank analyses. ETV6::RUNX1 and NTRK1 were isolated from patient cDNA and transduced into IL‐3–dependent Ba/F3 cells. Proliferation was assessed via CellTiter‐Glo‐2.0 with the addition of the TrkA agonist, nerve growth factor (NGF). Sensitivity to the TRK inhibitor larotrectinib was assessed via Annexin V/7AAD staining and flow cytometry. Changes in TrkA signalling through effectors, ERK and AKT, were evaluated by western blotting.
Results
Patients with ETV6::RUNX1 had increased NTRK1 expression in comparison with other B‐ALL cases ( p < 0.0001), with those overexpressing NTRK1 exhibiting a trend towards increased relapse. in vitro experiments revealed that only Ba/F3 ETV6::RUNX1 + NTRK1 cells demonstrated IL‐3 independence, indicative of leukaemic transformation (vs parental Ba/F3, p < 0.0001). These cells were sensitive to larotrectinib (LD 50 161 nM) and significantly decreased phosphorylation of ERK and AKT (vs NGF p = 0.0004; p = 0.007, respectively).
Conclusion
NTRK1 overexpression has not previously been reported in B‐ALL and was associated with increased relapse in patients with ETV6::RUNX1 and NTKR1 overexpression. The in vitro success of larotrectinib treatment warrants further in vivo investigation and may be a viable therapeutic addition for patients with ETV6::RUNX1 B‐ALL and NTRK1 overexpression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- South Australian Health and Medical Research Institute (SAHMRI), Blood Cancer Program, Precision Cancer Medicine Theme, Adelaide, South Australia, Australia.
- Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.
- Women's and Children's Hospital, Adelaide, South Australia, Australia.
- Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG), Clayton, Victoria, Australia.
- Royal Adelaide Hospital, Adelaide, South Australia, Australia.
- Oncology Service, Children's Health Queensland Hospital and Health Service, Brisbane, Queensland, Australia.
ORCID-Profile: Barbara J McClure, Michael P Osborn, Andrew S Moore, Rishi S Kotecha, Susan L Heatley
Förderung
- National Health and Medical Research Council
- Medical Research Future Fund, Australia
- Channel 7 Children's Research Fund
- Leukaemia Foundation, Australia
- Cancer Council of South Australia
- The Kid's Cancer Project
Zitieren
APA
Quinlan, L., Page, E. C., Rehn, J., McClure, B. J., Osborn, M. P., Moore, A. S., Kotecha, R. S., Henderson, M. J., Martin, M., Alvaro, F., Yeung, D. T., White, D. L., & Heatley, S. L. (2025). High Expression of NTRK1 in ETV6::RUNX1 Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to Larotrectinib. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31983
Vancouver
Quinlan L, Page EC, Rehn J, McClure BJ, Osborn MP, Moore AS, et al. High Expression of NTRK1 in ETV6::RUNX1 Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to Larotrectinib. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31983
BibTeX
@article{Quinlan2025,
author = {Quinlan, Luke and Page, Elyse C and Rehn, Jacqueline and McClure, Barbara J and Osborn, Michael P and Moore, Andrew S and Kotecha, Rishi S and Henderson, Michelle J and Martin, Michelle and Alvaro, Frank and Yeung, David T and White, Deborah L and Heatley, Susan L},
title = {High Expression of NTRK1 in ETV6::RUNX1 Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to Larotrectinib},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31983}
}
EUVIMED